Company Valuation: Protalix BioTherapeutics, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 37.89 69.41 129.9 138.4 144.8 257.2 - -
Change - 83.2% 87.08% 6.6% 4.57% 77.66% - -
Enterprise Value (EV) 37.89 69.41 129.9 138.4 144.8 257.2 257.2 257.2
Change - 83.2% 87.08% 6.6% 4.57% 77.66% 0% 0%
P/E -1.34x -4.42x 19.8x 47x -22.5x 10.9x -305x 43.6x
PBR - - - - - - - -
PEG - 0.1x -0x -0.8x 0x -0x 3x -0x
Capitalization / Revenue 0.99x 1.46x 1.98x 2.59x 2.74x 2.91x 3.37x 3.34x
EV / Revenue 0x 0x 0x 0x 0x 2.91x 3.37x 3.34x
EV / EBITDA - - - - - - - -
EV / EBIT -0x -0x 0x 0x -0x 9.81x -150x 40x
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 -0.62 -0.31 0.09 0.04 -0.08 0.28 -0.01 0.07
Distribution rate - - - - - - - -
Net sales 1 38.35 47.64 65.49 53.4 52.74 88.42 76.28 76.97
EBITDA - - - - - - - -
EBIT 1 -20.46 -13.01 10.46 3.917 -5.5 26.21 -1.719 6.426
Net income 1 -27.58 -14.93 8.312 2.932 -6.604 23.02 -1.087 6.231
Net Debt - - - - - - - -
Reference price 2 0.832 1.370 1.780 1.880 1.800 3.050 3.050 3.050
Nbr of stocks (in thousands) 45,557 50,666 72,952 73,634 80,421 84,319 - -
Announcement Date 31/3/22 27/2/23 14/3/24 17/3/25 18/3/26 - - -
1USD in Million2USD
Estimates

P/E, Detailed evolution



P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
10.89x - - - 257M
42.25x14.3x30.31x0.47% 1,286B
41.82x7.01x19.73x1.87% 688B
37.62x8.63x17.81x2.34% 521B
21.75x5.27x13.2x2.48% 386B
104.88x5.98x25.49x2.3% 364B
24x5.82x14.17x2.73% 302B
24.25x4.85x13.63x1.8% 287B
24.04x7.38x13.56x2.17% 252B
-39.49x7.32x46.07x1.96% 208B
Average 29.20x 7.40x 21.55x 2.01% 429B
Weighted average by Cap. 37.57x 8.95x 22.68x 1.68%

Y-o-Y evolution of P/E

Valuation ratios - P/E - Protalix BioTherapeutics, Inc.

Historical PBR trend

Valuation ratios - PBR - Protalix BioTherapeutics, Inc.

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - Protalix BioTherapeutics, Inc.

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - Protalix BioTherapeutics, Inc.

  1. Stock Market
  2. Stocks
  3. PLX Stock
  4. Valuation Protalix BioTherapeutics, Inc.